Search Result

Results for "

P-gp

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P-glycoprotein (83) Akt (1) AMPK (1) Amylases (1) Amyloid-β (1) Antibiotic (3) Apoptosis (13) Autophagy (2) Bacterial (2) Bcl-2 Family (1) BCRP (11) Beta-secretase (2) c-Met/HGFR (2) Calcium Channel (10) Carbonic Anhydrase (1) Caspase (1) CCR (1) Cytochrome P450 (14) DNA/RNA Synthesis (1) Dopamine β-hydroxylase (1) Drug Metabolite (3) Endogenous Metabolite (7) FGFR (3) Glucosidase (1) Hedgehog (1) HIV (5) HIV Protease (5) iGluR (1) Isotope-Labeled Compounds (6) mAChR (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) NF-κB (2) p38 MAPK (1) Parasite (3) PARP (1) Potassium Channel (1) PPAR (1) Reactive Oxygen Species (1) SARS-CoV (6) Small Interfering RNA (siRNA) (1) TAM Receptor (2) Topoisomerase (1) Wee1 (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (86) Cardiovascular Disease (9) Infection (10) Inflammation/Immunology (5) Metabolic Disease (8) Neurological Disease (9)

By Targets:

P-glycoprotein (83)

Akt (1)

AMPK (1)

Amylases (1)

Amyloid-β (1)

Antibiotic (3)

Apoptosis (13)

Autophagy (2)

Bacterial (2)

Bcl-2 Family (1)

BCRP (11)

Beta-secretase (2)

c-Met/HGFR (2)

Calcium Channel (10)

Carbonic Anhydrase (1)

Caspase (1)

CCR (1)

Cytochrome P450 (14)

DNA/RNA Synthesis (1)

Dopamine β-hydroxylase (1)

Drug Metabolite (3)

Endogenous Metabolite (7)

FGFR (3)

Glucosidase (1)

Hedgehog (1)

HIV (5)

HIV Protease (5)

iGluR (1)

Isotope-Labeled Compounds (6)

mAChR (1)

Microtubule/Tubulin (2)

Mitochondrial Metabolism (1)

NF-κB (2)

p38 MAPK (1)

Parasite (3)

PARP (1)

Potassium Channel (1)

PPAR (1)

Reactive Oxygen Species (1)

SARS-CoV (6)

Small Interfering RNA (siRNA) (1)

TAM Receptor (2)

Topoisomerase (1)

Wee1 (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (86)

Cardiovascular Disease (9)

Infection (10)

Inflammation/Immunology (5)

Metabolic Disease (8)

Neurological Disease (9)

116

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157483

P-gp inhibitor 18	P-glycoprotein	Cancer
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of *P-gp. P-gp* inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a *P-gp* inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-144366

P-gp inhibitor 3	P-glycoprotein	Cancer
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .

HY-162040

P-gp inhibitor 17	P-glycoprotein	Cancer
P-gp inhibitor 17 (compound 2g) is a *P-gp* inhibitor directly interacted with the transmembrane domain of *P-gp. P-gp* inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-149813

P-gp inhibitor 14	P-glycoprotein	Cancer
P-gp inhibitor 14 (Compound 8a) is a high affinity *P-gp* inhibitor. P-gp inhibitor 14 reverses P-gp-mediated multidrug resistance (EC₅₀=48.74 nM). P-gp inhibitor 14 has a weak inhibitory effect on CYP3A4 activity .

HY-N144114

P-gp inhibitor 2	P-glycoprotein	Cancer
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-146117

P-gp modulator 2

P-glycoprotein Cancer

P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .
HY-146118

P-gp modulator 3

P-glycoprotein Cancer

P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

P-gp modulator 2	P-glycoprotein	Cancer
P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

P-gp modulator 3	P-glycoprotein	Cancer
P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

HY-155032

P-gp inhibitor 15	P-glycoprotein	Cancer
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-150565

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In ^TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-112912

P-gp modulator 1	P-glycoprotein	Cancer
P-gp modulator 1 is a high affinity, orally available modulator of P-glycoprotein (Pgp), can reverse the Pgp-mediated multidrug resistance ((MDR) .

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-101791

P-gp inhibitor 1

P-glycoprotein Cancer

P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

P-gp inhibitor 1	P-glycoprotein	Cancer
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

HY-144393

P-gp/BCRP-IN-1	BCRP	Cancer
P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of *P-gp* and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-RS10394

PGP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PGP Human Pre-designed siRNA Set A contains three designed siRNAs for PGP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PGP Human Pre-designed siRNA Set A PGP Human Pre-designed siRNA Set A

HY-155152

P-gp/BCRP-IN-2	P-glycoprotein BCRP	Cancer
P-gp/BCRP-IN-2 (compound 15) is an oxadiazole derivative and a dual inhibitor of the ABC transporter P-glycoprotein (IC₅₀: 1.6 nM) and BCRP (IC₅₀: 600 nM). P-gp/BCRP-IN-2 also enhances the anti-proliferative effects of Doxorubicin (HY-15142A) in drug-resistant human adenocarcinoma colon cancer cell lines HT29/DX and MDCK-MDR1 cells .

HY-N7120

Penicillin G procaine hydrate Pgp hydrate	Bacterial Antibiotic	Infection
Penicillin G Procaine hydrate (PGP hydrate), a β-lactam antibiotic, is a crystalline complex produced by chemically combining penicillin G with procaine .

HY-162369

PID-9	P-glycoprotein	Cancer
PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC₅₀ = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .

HY-W009141

1-Monopalmitin

Glyceryl palmitate
P-glycoprotein Cancer

1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

1-Monopalmitin Glyceryl palmitate	P-glycoprotein	Cancer
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N7305

Jatrophane 5	P-glycoprotein	Cancer
Jatrophane 5 is a natural product of Jatropha carcas L. Jatrophane 5 has powerful inhibition of *P-gp*, higher than R(+)-verapamil (HY-14275) and Tariquidar (HY-10550) in colorectal multi-drug resistant cells (DLD1-TxR) .

HY-146096

RMS3	P-glycoprotein Apoptosis	Cancer
RMS3, a tetrandrine analogue, is a potent P-glycoprotein (P-gp) inhibitor. RMS3 has markedly antiproliferative and cytotoxic effects on cancer cells. RMS3 causes PARP cleavage, a marker for cells undergoing apoptosis. RMS3 has strong anticancer property .

HY-U00247

MCI826

P-glycoprotein Cancer

MCI826 is a P-glycoprotein (P-gp) antagonist.

MCI826	P-glycoprotein	Cancer
MCI826 is a P-glycoprotein (P-gp) antagonist.

HY-A0064

Verapamil hydrochloride 40+ Cited Publications (±)-Verapamil hydrochloride; CP-16533-1 hydrochloride	Calcium Channel P-glycoprotein Cytochrome P450	Cardiovascular Disease
Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-14275

Verapamil 40+ Cited Publications (±)-Verapamil; CP-16533-1	Calcium Channel P-glycoprotein Cytochrome P450	Metabolic Disease Cancer
Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-N10562

Mutabilol	P-glycoprotein	Cancer
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-N0425

Epoxylathyrol	P-glycoprotein	Cancer
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-W700684

N-Didesmethyl Loperamide

R 21345
Others Others

N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

N-Didesmethyl Loperamide R 21345	Others	Others
N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

HY-B0777

Moxidectin 1 Publications Verification CL301423	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Inflammation/Immunology Cancer
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-10550A

Tariquidar methanesulfonate, hydrate Maximum Cited Publications 46 Publications Verification XR9576 methanesulfonate, hydrate	P-glycoprotein	Cancer
Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent and specific inhibitor of P-glycoprotein (P-gp) with a K_d of 5.1 nM.

HY-14275S1

Verapamil-d7 (±)-Verapamil-d₇; CP-16533-1-d₇	Isotope-Labeled Compounds Calcium Channel P-glycoprotein Cytochrome P450	Metabolic Disease Cancer
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-108694

γ-Tocotrienol 1 Publications Verification	Endogenous Metabolite NF-κB	Metabolic Disease Inflammation/Immunology
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .

HY-146097

RMS5	P-glycoprotein Apoptosis	Cancer
RMS5, a tetrandrine analogue, is a potent P-glycoprotein (P-gp) inhibitor. RMS5 has markedly antiproliferative and cytotoxic effects on cancer cells. RMS5 slightly diminishes the expression of the anti-apoptotic Bcl-2 family proteins Bcl-XL and Mcl-1. RMS3 causes PARP cleavage, a marker for cells undergoing apoptosis. RMS5 has strong anticancer property .

HY-N1457

Chrysosplenetin
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits *P-gp* activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-149277

FM04	P-glycoprotein	Cancer
FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC₅₀=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .

HY-A0064S1

Verapamil-d6 hydrochloride (±)-Verapamil-d₆ hydrochloride; CP-16533-1-d₆ hydrochloride	Isotope-Labeled Compounds	Cardiovascular Disease
Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-10550

Tariquidar Maximum Cited Publications 46 Publications Verification XR9576	P-glycoprotein	Cancer
Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-110377

Tariquidar dihydrochloride XR9576 dihydrochloride	P-glycoprotein	Cancer
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-B0777R

Moxidectin (Standard) CL301423 (Standard)	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (Standard) is the analytical standard of Moxidectin. This product is intended for research and analytical applications. Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-100750

Norverapamil hydrochloride 1 Publications Verification (±)-Norverapamil hydrochloride; D591 hydrochloride	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

HY-135328

Norverapamil (±)-Norverapamil; D591	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W009141

1-Monopalmitin Glyceryl palmitate	Source classification Plants	P-glycoprotein
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N7305

Jatrophane 5	Structural Classification Terpenoids Source classification Euphorbia peplus Linn. Diterpenoids Euphorbiaceae Plants	P-glycoprotein
Jatrophane 5 is a natural product of Jatropha carcas L. Jatrophane 5 has powerful inhibition of *P-gp*, higher than R(+)-verapamil (HY-14275) and Tariquidar (HY-10550) in colorectal multi-drug resistant cells (DLD1-TxR) .

HY-N10562

Mutabilol	Terpenoids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Diterpenoids Plants	P-glycoprotein
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-N0425

Epoxylathyrol	Structural Classification Classification of Application Fields Euphorbia boetica Terpenoids Source classification Diterpenoids Euphorbiaceae Plants Disease Research Fields Cancer	P-glycoprotein
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-N2453

Convallatoxin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants Inflammation/Immunology Disease Research Fields	PPAR NF-κB P-glycoprotein
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-108694

γ-Tocotrienol 1 Publications Verification	Structural Classification Monophenols other families Microorganisms Classification of Application Fields Source classification Phenols Plants Inflammation/Immunology Disease Research Fields	Endogenous Metabolite NF-κB
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .

HY-N0689

Evodine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	P-glycoprotein
Evodine, the major limonoid of Evodiae Fuctus, is a potent *P-gp* inhibitor. Evodine has protection against glutamateinduced toxicity by preserving the antioxidant defense system .

HY-N10563

Coleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
Coleon-U-quinone is a potent *P-gp* inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits *P-gp* activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-N4108

Hypophyllanthin	Phyllanthus urinaria Linn. Structural Classification Classification of Application Fields Source classification Lignans Euphorbiaceae Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	P-glycoprotein
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-N6748

Roquefortine C	Infection Microorganisms Classification of Application Fields Cyclopeptides Source classification Disease Research Fields	P-glycoprotein Cytochrome P450 Bacterial Endogenous Metabolite
Roquefortine C, a fungal cyclopeptide isolated from Penicillium roquefortii, activates *P-gp* and also inhibits P450-3A and other haemoproteins. Roquefortine C has bacteriostatic activities against Gram-positive bacteria .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou Saponin VII	Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of *P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-126940

Furanodiene	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Curcuma longa Disease Research Fields Cancer Zingiberaceae	Reactive Oxygen Species P-glycoprotein Apoptosis
Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae. Furanodiene plays anti-cancer effects through anti-angiogenesis and inducing ROS production, DNA strand breaks and apoptosis. Furanodiene suppresseed efflux transporter *Pgp* (P-glycoprotein) function and reduced Pgp protein level .

HY-N3308

Medicarpin	Structural Classification Monophenols Classification of Application Fields Leguminosae Source classification Phenols Plants Disease Research Fields Cancer Medicago sativa L.	Apoptosis
Medicarpin is a flavonoid isolated from Medicago sativa. Medicarpin induces apoptosis and overcome multidrug resistance in leukemia P388 cells by modulating P-gp-mediated efflux of agents .

HY-N2103

Tenacissoside G	Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Steroids Cancer	P-glycoprotein
Tenacissoside G is a C21 steroid from the stems of Marsdenia tenacissima. Tenacissoside G reverses multidrug resistance in P-glycoprotein (Pgp)-overexpressing multidrug-resistant cancer cells .

HY-N6684

Deoxynivalenol 4 Publications Verification Vomitoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Others
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N7332

Pepluanin A	Structural Classification Terpenoids Source classification Euphorbia peplus Linn. Diterpenoids Euphorbiaceae Plants	P-glycoprotein
Pepluanin A is a natural compound isolated from Euphorbia peplus L. Pepluanin A shows a very high activity for a jatrophane diterpene, outperforming Cyclosporin A by a factor of at least 2 in the inhibition of Pgp-mediated Daunomycin (HY-13062A) transport ^[1]

HY-N3028

Taccalonolide B	Structural Classification Classification of Application Fields Source classification Schizocapsa plantaginea Hance Plants Disease Research Fields Taccaceae Steroids Cancer	Microtubule/Tubulin
Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC₅₀ of 208 nM .

HY-N2416

Taccalonolide A	Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Tacca chantrieri Andre Taccaceae Steroids Cancer	Microtubule/Tubulin Apoptosis
Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities . Taccalonolide A causes G₂-M accumulation, Bcl-2 phosphorylation and initiation of apoptosis . Taccalonolide A is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug resistance protein 7 (MRP7), with an IC₅₀ of 622 nM for SK-OV-3 cells .

HY-N6972

Cepharanthine 3 Publications Verification	Infection Structural Classification Alkaloids Stephania cepharantha Hayata Classification of Application Fields Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Menispermaceae Stephania japonica (Thunb.) Miers	SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 µM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

Species:	Human (5) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	His (6) Avi (1) Fc (2)
Source:	HEK293 (5) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P71096

	UCHL1 Protein, Human (His) Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1; UCH-L1; Neuron Cytoplasmic Protein 9.5; Pgp 9.5; Pgp9.5; Ubiquitin Thioesterase L1; UCHL1	Human	E. coli
	The UCHL1 protein is a multifunctional deubiquitinase that regulates a variety of cellular processes. It maintains synaptic and cardiac function, modulates inflammatory responses, and influences osteoclastogenesis. UCHL1 Protein, Human (His) is the recombinant human-derived UCHL1 protein, expressed by E. coli , with C-6*His labeled tag. The total length of UCHL1 Protein, Human (His) is 223 a.a., with molecular weight of ~26.0 kDa.

HY-P74483

	UCHL1 Protein, Rat (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; Uchl1; Pgp9.5	Rat	E. coli
	The UCHL1 protein is a ubiquitin proteolytic enzyme essential for processing ubiquitin precursors and hydrolyzing ubiquitinated proteins. As a thiol protease, it specifically cleaves the C-terminal glycine of ubiquitin. UCHL1 Protein, Rat (His) is the recombinant rat-derived UCHL1 protein, expressed by E. coli , with N-10*His labeled tag. The total length of UCHL1 Protein, Rat (His) is 222 a.a., with molecular weight of ~28 kDa.

HY-P70507

	CD44 Protein, Human (HEK293, His) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (HEK293, His) is the recombinant human-derived CD44 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD44 Protein, Human (HEK293, His) is 200 a.a., with molecular weight of 38-50 kDa.

HY-P700402

	CD44 Protein, Human (Biotinylated, HEK293) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (Biotinylated, HEK293) is the recombinant human-derived CD44 protein, expressed by HEK293 , with C-Avi, C-mFc labeled tag. The total length of CD44 Protein, Human (Biotinylated, HEK293) is 200 a.a., with molecular weight of 51 kDa.

HY-P73466

	UCHL1 Protein, Mouse (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; Uchl1; Pgp9.5	Mouse	E. coli
	UCHL1 Protein, a ubiquitin carboxyl-terminal hydrolase, plays a crucial role in protein degradation and regulation of cellular processes. It is involved in maintaining neuronal integrity and has been linked to neurodegenerative diseases. UCHL1 Protein's potential as a biomarker and therapeutic target in neurodegenerative disorders makes it a subject of intense research in the field of neuroscience. UCHL1 Protein, Mouse (His) is the recombinant mouse-derived UCHL1 protein, expressed by E. coli , with N-His labeled tag. The total length of UCHL1 Protein, Mouse (His) is 222 a.a., with molecular weight of ~29 kDa.

HY-P700439

	CD44 Protein, Macaca fascicularis (HEK293, His) CD44 Antigen; CDw44; Epican; Extracellular Matrix Receptor III; ECMR-III; gp90 Lymphocyte Homing/Adhesion Receptor; HUTCH-I; Heparan Sulfate Proteoglycan; Hermes Antigen; Hyaluronate Receptor; Phagocytic Glycoprotein 1; Pgp-1; Phagocytic Glycoprotein I; Pgp-I; CD44; LHR	Cynomolgus	HEK293
	The CD44 protein is characterized by a lack of conserved residues critical for annotation of propagation signatures. This defective residue in CD44 prevents the propagation of specific functional features associated with this protein. CD44 Protein, Macaca fascicularis (HEK293, His) is the recombinant cynomolgus-derived CD44 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of CD44 Protein, Macaca fascicularis (HEK293, His) is 630 a.a., with molecular weight of 71.6 kDa.

HY-P700966

	CD44 Protein, Human (242a.a, HEK293, hFc) CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; Pgp-I; CSPG8; HCELL; HUTCH-I; IN; MC56	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (242a.a, HEK293, hFc) is a recombinant protein dimer complex containing human-derived CD44 protein, expressed by HEK293 , with C-hFc labeled tag. CD44 Protein, Human (242a.a, HEK293, hFc), has molecular weight of 70-100 kDa.

HY-P700967

	CD44 Protein, Human (242a.a, HEK293, His) CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; Pgp-I; CSPG8; HCELL; HUTCH-I; IN; MC56	Human	HEK293
	CD44 is a cell surface receptor that plays a key role in calcium mobilization and actin-mediated cytoskeletal reorganization, cell migration, and adhesion. CD44 Protein, Human (242a.a, HEK293, His) is a recombinant protein dimer complex containing human-derived CD44 protein, expressed by HEK293 , with C-His labeled tag. CD44 Protein, Human (242a.a, HEK293, His), has molecular weight of 45-68 kDa.

Cat. No.	Product Name	Chemical Structure

HY-A0064S1

Verapamil-d6 hydrochloride

Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-135328AS

Norverapamil-d7 hydrochloride
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-A0064S

Verapamil-d3 hydrochloride

Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

HY-14275S1

Verapamil-d7
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-135328S

Norverapamil-d7
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks